Vol. 66 No. 5 (2012), Drug profile
Vol. 66 No. 5 (2012)

Budenofalk 2 mg rectal foam represents a major new option in the treatment of patients with ulcerous colitis

Drug profile
Published 13. 10. 2014
Milan Lukáš
IBD clinical and research centre ISCARE a.s., Prague, Czech Republic
PDF

Keywords

farmakoterapie - management
hodnocení léčiv
lidé
pharmacotherapy
ulcerative colitis
aplikace rektální
budesonid
budesonide
ulcerózní kolitida